March 16, 2023

March 16, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.

March 16, 2023

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity

March 16, 2023

ASH 2022: Dr. Jennifer Woyach on Targeting Venetoclax-Resistant Chronic Lymphocytic Leukemia (CLL) with a PROTAC-Based BCL-2/BCL-XL Protein Degrader

A novel PROTAC-based BCL-2/BCL-XL degrader was able to cause cell death in laboratory models of venetoclax-resistant chronic lymphocytic leukemia (CLL).

March 16, 2023

ASH 2022: Dr. Jennifer Woyach on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a BTK Inhibitor

Pirtobrutinib continues to demonstrate promising and durable efficacy in heavily pre-treated patients with relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), who have been previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor. Pirtobrutinib may be an important option to extend the benefit of BTK inhibition among patients

March 16, 2023

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

Targeted therapies have greatly improved survival outcomes for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For example, Ibrutinib is so effective at controlling CLL/SLL that the overall survival of patients treated with first-line ibrutinib is no different from that of the general population.

March 16, 2023

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who achieved undetectable measurable (or minimal) residual disease (uMRD) after fixed-duration ibrutinib + venetoclax treatment continue to have excellent outcomes four years after stopping initial therapy. The results of this study suggest that if patients achieve uMRD remission,

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

March 16, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter Syndrome

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

ASH 2022: Dr. Jennifer Woyach on Targeting Venetoclax-Resistant Chronic Lymphocytic Leukemia (CLL) with a PROTAC-Based BCL-2/BCL-XL Protein Degrader

ASH 2022: Dr. Jennifer Woyach on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Previously Treated with a BTK Inhibitor

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT